Announced on behalf of subsidiary,Tanvex Biologics
Corporation,directors and supervisor change
Date of events
2022/04/22
To which item it meets
paragraph 6
Statement
1.Date of occurrence of the change:2022/04/22
2.Name of legal person:Tanvex BioPharma, Inc.
3.Name of the previous position holder:
Director
Tanvex BioPharma, Inc. Representative: Yen, Yun
Tanvex BioPharma, Inc. Representative: Allen Chao
Tanvex BioPharma, Inc. Representative: Nelson Hsu
Supervisor
Tanvex BioPharma, Inc. Representative: Ying Yu Guo
4.Resume of the previous position holder:
Director
Tanvex BioPharma, Inc. Representative: Yen, Yun
Tanvex BioPharma, Inc. Representative: Allen Chao
Tanvex BioPharma, Inc. Representative: Nelson Hsu
Supervisor
Tanvex BioPharma, Inc. Representative: Ying Yu Guo
5.Name of the new position holder:
Director
Tanvex BioPharma, Inc. Representative: Yen, Yun
Tanvex BioPharma, Inc. Representative: Allen Chao
Tanvex BioPharma, Inc. Representative: Nelson Hsu
Supervisor
Tanvex BioPharma, Inc. Representative: Jang Yang Chang
6.Resume of the new position holder:
Director
Tanvex BioPharma, Inc. Representative: Yen, Yun
Tanvex BioPharma, Inc. Representative: Allen Chao
Tanvex BioPharma, Inc. Representative: Nelson Hsu
Supervisor
Tanvex BioPharma, Inc. Representative: Jang Yang Chang
7.Reason for the change:term expired
8.Original term (from __________ to __________):2019/3/27 to 2022/3/26
9.Effective date of the new appointment:2022/04/22
10.Any other matters that need to be specified:
The change in directors exceeds one-third of the number of directors.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 22 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 April 2022 09:37:07 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.